Skip navigation

Ensure Compliance in Specialty Pharmacy Arrangements, Patient Support Programs and Evolving Drug Pricing Transparency Legislation

December 4-5, 2018
  • Philadelphia, PA

With the current administration moving forward with its blueprint to lower drug costs, the OIG/HHS announcing a ruling to potentially remove safe harbor protection for drug rebates and evolving state drug pricing transparency legislation, pharmaceutical manufacturers must be more vigilant than ever in managing compliance risks within managed markets.

In its third year, CBI’s Managed Markets Compliance Congress convenes top industry compliance and legal leaders to discuss the increased challenges and complexity in structuring contracts with the healthcare value chain and ensure compliant interactions with specialty pharmacies and patient support programs.

Discuss Top Compliance Issues Affecting Managed Markets Activities:

  • Learn from veteran prosecutors about the impact of current enforcement priorities on managed markets compliance
  • Discuss the potential effect of the removal of safe harbor for drug rebates on payor contracting and value-based agreements
  • Explore the rise in state drug pricing transparency laws —
    Review new requirements under these laws going into effect in 2019
  • Ensure compliant interactions with specialty pharmacies, wholesalers and distributors
  • Mitigate fraud and abuse risks with patient support programs — Examine best practices to manage donations to charitable foundations
  • Understand current trends of how companies are managing bona fide service fees and why it is important
  • Review strategies to implement FDA guidance on payor communications — Evaluate the unique challenges of engaging with payors and how to set up effective monitoring and training


Best conference I have attended. All material was very relevant, speakers were on point, sharp and insightful. Timing allocation was also excellent.

Senior Compliance Manager, Johnson & Johnson

Great conference with speakers who are industry leaders. Smaller group allowed for more open dialogue and sharing of information.

Senior Analyst Compliance, Bayer Healthcare

I look forward to attending CBI for the candid discussions and presentations regarding the pharmaceutical compliance environment.

Government Contracting & Pricing Compliance Officer,
Johnson & Johnson